Dexcom G7 CGM Proven Effective in Non-Insulin Type 2 Diabetes: CONNECT Study
Key Questions
What were the key results of the CONNECT study on Dexcom G7?
In non-insulin-treated type 2 diabetes patients, Dexcom G7 CGM achieved a 0.9% greater A1C reduction and five additional hours of time in range daily versus self-monitoring of blood glucose.
Were the benefits of Dexcom G7 consistent across patient groups?
Yes, improvements held across diverse demographics and medication classes. This Level A evidence may expand CGM access beyond insulin users as standard care.
How could the CONNECT study impact diabetes management guidelines?
Findings support broader CGM adoption in type 2 diabetes, potentially shifting practice away from SMBG alone. The results were presented at ADA 2026.
The CONNECT study presented at ADA 2026 shows Dexcom G7 continuous glucose monitoring in non-insulin-treated T2D patients leads to 0.9% greater A1C reduction vs self-monitoring blood glucose, with 5 hours more time in range per day. Benefits were consistent across demographics and medication classes. This level A evidence could shift standard of care, expanding CGM use beyond insulin users.